Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion:~* COVID-19+ in past 14 days~* Platelets \> 100,000~* eGFR \> 30ml/min~Exclusion:~* Hospitalized~* Contradiction/ other indication for anti-coagulation~* Pregnancy~* Active cancer

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Apixaban 2.5mg (Type: ACTIVE_COMPARATOR): Anticoagulation: prophylactic dose Apixaban 2.5mg po bid
- Apixaban 5mg (Type: ACTIVE_COMPARATOR): Anticoagulation: therapeutic dose Apixaban 5.0mg po bid
- Aspirin (Type: ACTIVE_COMPARATOR): Antiplatelet agent: low dose aspirin 81mg po qd
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).